Sorrento Therapeutics, Inc.
SRNE
$0.001
$0.000111.11%
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 15.03M | 16.25M | 15.59M | 17.40M | 11.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.03M | 16.25M | 15.59M | 17.40M | 11.46M |
| Cost of Revenue | 41.72M | 48.99M | 54.77M | 76.26M | 54.17M |
| Gross Profit | -26.70M | -32.74M | -39.17M | -58.86M | -42.71M |
| SG&A Expenses | 48.94M | 54.98M | 39.46M | 50.16M | 48.14M |
| Depreciation & Amortization | 1.13M | 1.13M | 1.13M | 1.13M | 1.04M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.79M | 105.10M | 95.36M | 127.54M | 103.34M |
| Operating Income | -76.77M | -88.85M | -79.77M | -110.14M | -91.88M |
| Income Before Tax | -107.87M | -143.16M | -228.93M | -91.64M | -220.53M |
| Income Tax Expenses | 671.00K | 11.47M | -1.81M | -1.02M | -1.05M |
| Earnings from Continuing Operations | -108.54M | -154.63M | -227.11M | -90.63M | -219.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 13.32M | 15.01M | 3.42M | 1.05M | 718.00K |
| Net Income | -95.21M | -139.62M | -223.69M | -89.58M | -218.76M |
| EBIT | -76.77M | -88.85M | -79.77M | -110.14M | -91.88M |
| EBITDA | -73.17M | -85.22M | -76.41M | -106.79M | -88.65M |
| EPS Basic | -0.17 | -0.26 | -0.46 | -0.20 | -0.54 |
| Normalized Basic EPS | -0.07 | -0.08 | -0.12 | -0.15 | -0.15 |
| EPS Diluted | -0.17 | -0.26 | -0.46 | -0.20 | -0.54 |
| Normalized Diluted EPS | -0.07 | -0.08 | -0.12 | -0.15 | -0.15 |
| Average Basic Shares Outstanding | 551.28M | 543.14M | 484.46M | 451.62M | 402.80M |
| Average Diluted Shares Outstanding | 551.28M | 543.14M | 484.46M | 451.62M | 402.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.01% | -- | -- | -- | -- |
